155 related articles for article (PubMed ID: 7829529)
1. A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.
Elsea SH; Hsiung Y; Nitiss JL; Osheroff N
J Biol Chem; 1995 Jan; 270(4):1913-20. PubMed ID: 7829529
[TBL] [Abstract][Full Text] [Related]
2. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Hsiung Y; Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1995 Sep; 270(35):20359-64. PubMed ID: 7657608
[TBL] [Abstract][Full Text] [Related]
3. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.
Dong J; Walker J; Nitiss JL
J Biol Chem; 2000 Mar; 275(11):7980-7. PubMed ID: 10713116
[TBL] [Abstract][Full Text] [Related]
4. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.
Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1992 Jul; 267(19):13150-3. PubMed ID: 1320012
[TBL] [Abstract][Full Text] [Related]
6. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
Strumberg D; Nitiss JL; Dong J; Walker J; Nicklaus MC; Kohn KW; Heddle JG; Maxwell A; Seeber S; Pommier Y
Antimicrob Agents Chemother; 2002 Sep; 46(9):2735-46. PubMed ID: 12183223
[TBL] [Abstract][Full Text] [Related]
7. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
8. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Moynihan M; Sutcliffe JA; Osheroff N
J Biol Chem; 1991 Aug; 266(22):14585-92. PubMed ID: 1650363
[TBL] [Abstract][Full Text] [Related]
9. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
10. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
O'Reilly EK; Kreuzer KN
Biochemistry; 2002 Jun; 41(25):7989-97. PubMed ID: 12069589
[TBL] [Abstract][Full Text] [Related]
11. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.
Froelich-Ammon SJ; Patchan MW; Osheroff N; Thompson RB
J Biol Chem; 1995 Jun; 270(25):14998-5004. PubMed ID: 7797481
[TBL] [Abstract][Full Text] [Related]
13. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
14. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Jannatipour M; Liu YX; Nitiss JL
J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
[TBL] [Abstract][Full Text] [Related]
15. A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP.
Sabourin M; Byl JA; Hannah SE; Nitiss JL; Osheroff N
J Biol Chem; 1998 Oct; 273(44):29086-92. PubMed ID: 9786915
[TBL] [Abstract][Full Text] [Related]
16. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
17. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Corbett AH; Hong D; Osheroff N
J Biol Chem; 1993 Jul; 268(19):14394-8. PubMed ID: 8390992
[TBL] [Abstract][Full Text] [Related]
18. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
19. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Osheroff N
Antimicrob Agents Chemother; 1992 Apr; 36(4):751-6. PubMed ID: 1323952
[TBL] [Abstract][Full Text] [Related]
20. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]